IFX regulates the abnormal immunity of IBD patients with tumor necrosis factor-α (TNF-α) as a therapeutic target, and domestic and foreign studies have confirmed its efficacy in treating IBD [11–13]. Here, TNF is linked to inflammatory bowel disease.